Quantcast

Latest Vectibix Stories

2014-05-31 08:21:10

Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix(®)) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin(®)) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). The...

2014-05-23 20:21:52

GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen's Vectibix(R) (panitumumab) in treatment of metastatic colorectal cancer - FDA approval (PMA) of therascreen KRAS RGQ PCR Kit for Vectibix expands QIAGEN's leadership in molecular companion diagnostics for personalized healthcare - QIAGEN driving the adoption of molecular tests...

2014-05-23 16:24:12

Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND OAKS, Calif., May 23, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Vectibix(® )(panitumumab) for use in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as first-line treatment in patients with...

2014-04-03 12:30:35

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth SummaryGBI Research, has released the pharma report "Monoclonal...

2013-12-30 08:26:41

LONDON, Dec. 30, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Colorectal Cancer -- KOL Insight Module IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader Roche/Genetech's Avastin and how do leading clinicians view the changes? The main drivers...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related